COMMUNIQUÉS West-GlobeNewswire

-
NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers
10/01/2025 - 14:05 -
NCCN Guidelines Updated to Include ctDNA-MRD Testing Recommendation for B-Cell Lymphoma
10/01/2025 - 14:03 -
RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025
10/01/2025 - 14:00 -
Galectin Therapeutics to Present at the 2025 MASH-TAG Conference
10/01/2025 - 14:00 -
World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering
10/01/2025 - 14:00 -
Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change
10/01/2025 - 14:00 -
ORYZON to Provide Corporate Progress Updates at Several Events in January-February
10/01/2025 - 14:00 -
scPharmaceuticals Provides Preliminary Unaudited Fourth Quarter and Full Year 2024 Financial Results
10/01/2025 - 14:00 -
Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History
09/01/2025 - 22:30 -
Voting Rights and Shares Capital of the Company
09/01/2025 - 22:15 -
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social
09/01/2025 - 22:15 -
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025
09/01/2025 - 22:05 -
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year 2024
09/01/2025 - 22:05 -
Aptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY Trial
09/01/2025 - 22:00 -
Mural Oncology Highlights Pipeline Progress and Anticipated 2025 Catalysts
09/01/2025 - 22:00 -
BioV Life Science and Regenerative Medicine International Summit Successfully Concludes, Leading the Future of Regenerative Medicine
09/01/2025 - 22:00 -
Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)
09/01/2025 - 22:00 -
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09/01/2025 - 21:38 -
Partnering to Save Lives, NMDP and the American Football Coaches Association Promote Student Athlete Philanthropy
09/01/2025 - 21:30
Pages